18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Inclusion Criteria

• •Age ≥ 18 years old
• •Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:
• •* DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of the elderly; OR
• •* primary mediastinal (thymic) large B cell lymphoma
• •* transformation of follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukemia to DLBCL will also be included
• •Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the following criteria:
• •* At least one measureable lesion away from head \& neck, liver, kidneys, GI tract and bladder
• •* At least one biopsy-accessible lesion or lymph node.
• •Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible lesion or lymph node.
• •Scheduled to receive commercial or research CAR T cell therapy with axicabtagene ciloleucel (Yescarta ®) as part of anticancer therapy.
• •Adequate renal and hepatic function, defined as:
• •1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr \< 1.6 mg/dL
• •2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x upper limit of normal (ULN)
• •3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
• •Able to give informed consent. Subjects unable to give informed consent will not be eligible for this study